TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32616493

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sociodemographic, health status, workplace information, work commuting information, driving behaviour, history of RCI
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Checklist of Individual Strength Questionnaire
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 21-item Depression Anxiety and Stress Scale
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Utrecht's Work Engagement Scale
Number of subjects: 375
Study: 32616499

Group type: EXPERIMENTAL
Intervention: Early progressive disease (PD; time to progression, TTP ≤18 months)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Late progressive disease (TTP >18 months)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: No progressive disease
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: At least very good partial response rate
Number of subjects: 926
Study: 32616515

Group type: EXPERIMENTAL
Intervention: Topical ASN008 gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical ASN008 gel (once-daily application for 5 days)
Number of subjects: 0
Study: 32616555

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus pembrolizumab (200 mg IV every 3 weeks for four doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus pembrolizumab
Number of subjects: 28
Study: 32616557

Group type: EXPERIMENTAL
Intervention: Lutathera 3.7 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lutathera 7.4 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lutathera plus nivolumab
Number of subjects: 9
Study: 32616759

Group type: EXPERIMENTAL
Intervention: Single infusion of autologous umbilical cord blood
Number of subjects: 0
Study: 32616802

Group type: EXPERIMENTAL
Intervention: EuroScore 2
Number of subjects: 4980

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 4980

Group type: EXPERIMENTAL
Intervention: Combined model of EuroScore 2 and BNP
Number of subjects: 4980
Study: 32616867

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (three monthly injections followed by PRN regimen)
Number of subjects: 32
Study: 32617173

Group type: EXPERIMENTAL
Intervention: mHealth intervention designed for psychiatric PTSD patients as a therapy add-on
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32617429

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) targeting sitting balance for 30-45 min daily for 10-12 sessions
Number of subjects: 76

Group type: COMPARATOR
Intervention: Virtual reality (VR) with limited arm movement for 30-45 min daily for 10-12 sessions
Number of subjects: 76
Study: 32617435

Group type: EXPERIMENTAL
Intervention: Body therapy treatment as add-on to treatment as usual
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study: 32617453

Group type: EXPERIMENTAL
Intervention: Multistrain probiotic (4 capsules of Vivomixx)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multistrain probiotic
Number of subjects: 50
Study: 32617528

Group type: EXPERIMENTAL
Intervention: Opt-In Treatment Approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Opt-Out Treatment Approach
Number of subjects: 20
Study: 32617582

Group type: EXPERIMENTAL
Intervention: Rituximab (1 g each, two courses, 2 weeks apart at the beginning and again at 6 months)
Number of subjects: 11
Study: 32617641

Group type: EXPERIMENTAL
Intervention: Gallium-68-labelled somatostatin analogue (SSA) PET
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluorine-18-labelled alternative
Number of subjects: 12
Study: 32617919

Group type: EXPERIMENTAL
Intervention: ORBERA® Intragastric Balloon System (IGB) as an adjunct to lifestyle intervention
Number of subjects: 258
Study: 32618009

Group type: EXPERIMENTAL
Intervention: DAPT for ≤12 months post discharge
Number of subjects: 12922

Group type: EXPERIMENTAL
Intervention: DAPT for >12 months post discharge
Number of subjects: 12922

Group type: COMPARATOR
Intervention: Not on DAPT at 12 months
Number of subjects: 12922
Study: 32618282

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32618486

Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32618572

Group type: EXPERIMENTAL
Intervention: Rose app intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study: 32618618

Group type: EXPERIMENTAL
Intervention: Complete cytoreductive surgery with greater omentectomy
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Pathological evidence of omental tumor involvement
Number of subjects: 337
Study: 32618687

Group type: EXPERIMENTAL
Intervention: Rapid response electroencephalography
Number of subjects: 181
Study: 32618884

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg or 25 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 7020

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7020
Study: 32619006

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study: 32619039

Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 9469

Group type: COMPARATOR
Intervention: Colloid
Number of subjects: 9469

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 9469

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 9469

Group type: COMPARATOR
Intervention: Lower limb compression
Number of subjects: 9469

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 9469
Study: 32619077

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole (600 mg for Asian non-Japanese patients; 300 mg for Japanese patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib plus endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib combined with endocrine therapy
Number of subjects: 0
Study: 32619115

Group type: EXPERIMENTAL
Intervention: Blinatumomab, a CD19 BiTE, administered to adults with MRD BCP-ALL after chemotherapy.
Number of subjects: 0
Study: 32619621

Group type: EXPERIMENTAL
Intervention: Total inflow and outflow vascular clamping (study group)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Inflow and outflow vascular clamping only of the segment harboring the tumor (control group)
Number of subjects: 230
Study: 32619740

Group type: EXPERIMENTAL
Intervention: Common genetic variants near SCN5A/SCN10A
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Common variants near HEY2
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Rare and low-frequency variants
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: SCN5A sequencing
Number of subjects: 586
Study: 32620006

Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) system (electronic alert and standardized care pathway)
Number of subjects: 225
Study: 32620116

Group type: EXPERIMENTAL
Intervention: CareWell integrated care model
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular care procedures (Control)
Number of subjects: 200
Study: 32620161

Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service intensity
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Caregiver perceptions of environmental support
Number of subjects: 139
Study: 32620211

Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg every two weeks until progression or unacceptable toxicity
Number of subjects: 32
Study: 32620404

Group type: EXPERIMENTAL
Intervention: Delphi-derived scale for aesthetic assessment
Number of subjects: 61
Study: 32620494

Group type: EXPERIMENTAL
Intervention: Nomogram model based on 10 independent variables (SYNTAX score, critical preoperative state, left ventricular ejection fraction, angina at rest, poor mobility, recent potent antiplatelet use, estimated glomerular filtration rate, body mass index, sex, age)
Number of subjects: 7352

Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 7352
Study: 32620520

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE) using irinotecan-eluting beads (LifePearl® Microspheres)
Number of subjects: 0
Study: 32620536

Group type: EXPERIMENTAL
Intervention: olipudase alfa
Number of subjects: 5
Study: 32620676

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Normal weight
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 3719

Group type: EXPERIMENTAL
Intervention: Sepsis subcohort
Number of subjects: 3719
Study: 32621083

Group type: EXPERIMENTAL
Intervention: Once-weekly dulaglutide (1.5 mg and 0.75 mg)
Number of subjects: 787
Study: 32621250

Group type: EXPERIMENTAL
Intervention: Iatrogenic PTB
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Spontaneous preterm labour (SPL)
Number of subjects: 987

Group type: EXPERIMENTAL
Intervention: Preterm prelabour rupture of membranes (PPROM)
Number of subjects: 987

Group type: COMPARATOR
Intervention: Generalised Estimating Equations approach
Number of subjects: 987
Study: 32621644

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 32621959

Group type: EXPERIMENTAL
Intervention: Bipolar disorder depression patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 37
Study: 32622665

Group type: EXPERIMENTAL
Intervention: Serum high sensitivity C-reactive protein (hsCRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sputum neutrophil elastase
Number of subjects: 0
Study: 32622695

Group type: EXPERIMENTAL
Intervention: Plasma ADMA concentrations in RA patients
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Plasma hArg concentrations in RA patients
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Presence of endothelial dysfunction (ED) in RA patients
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ln-RHI in RA patients
Number of subjects: 164
Study: 32622774

Group type: EXPERIMENTAL
Intervention: QC-DeMo (deprescribing module in interprofessional quality circles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDeI (deprescribing-focused medication review)
Number of subjects: 0
Study: 32622884

Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg q.d.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Futibatinib 8-200 mg t.i.w. or 4-24 mg q.d.
Number of subjects: 86
Study: 32623075

Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients
Number of subjects: 82

Group type: COMPARATOR
Intervention: ctDNA-positive patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: ctDNA positivity
Number of subjects: 82
Study: 32623096

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 261
Study: 32623316

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study: 32623367

Group type: EXPERIMENTAL
Intervention: Narrative e-Writing Intervention (NeW-I)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 32623479

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 59
Study: 32623724

Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound plus exercise
Number of subjects: 1025
Study: 32624004

Group type: EXPERIMENTAL
Intervention: Supervised in-hospital physical activity program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study: 32624195

Group type: EXPERIMENTAL
Intervention: Sofosbuvir monotherapy
Number of subjects: 0
Study: 32624280

Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with 400 mg testosterone cypionate intramuscularly every 28 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) followed by AR-targeted therapy rechallenge
Number of subjects: 59
Study: 32624458

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for low CFC lesions
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for normal CFC lesions
Number of subjects: 1397

Group type: COMPARATOR
Intervention: Deferred PCI for lesions with FFR ≤0.8 and normal CFC
Number of subjects: 1397
Study: 32625123

Group type: EXPERIMENTAL
Intervention: 6-month exercise intervention (150 min per week)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 314
Study: 32625143

Group type: EXPERIMENTAL
Intervention: SAMPLE-PE intervention (specific details not provided)
Number of subjects: 0
Study: 32625239

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 2076

Group type: COMPARATOR
Intervention: Metabolically unhealthy individuals (MUNO, MUO)
Number of subjects: 2076
Study: 32627114

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) treatment at the graft vein junction after successful percutaneous thrombectomy.
Number of subjects: 20
Study: 32627589

Group type: EXPERIMENTAL
Intervention: Social media advertising (Facebook)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted mailing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-person solicitation of clinic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of recruitment strategies
Number of subjects: 0
Study: 32627860

Group type: COMPARATOR
Intervention: Resilience training (combined theoretical foundation including mindfulness and cognitive-behavioral therapy)
Number of subjects: 6892
Study: 32628342

Group type: EXPERIMENTAL
Intervention: Current chronic graft-vs-host disease
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Fatigue and physical function
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Distress and social support
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Final model including all factors
Number of subjects: 279
Study: 32628583

Group type: EXPERIMENTAL
Intervention: Docetaxel given every 3 weeks for 4 cycles plus subcutaneous trastuzumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Docetaxel and subcutaneous trastuzumab
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 60
Study: 32628945

Group type: EXPERIMENTAL
Intervention: Cigarette Purchase Task (CPT)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Heaviness of Smoking Index (HSI)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: FTND total scores minus items 1 and 4
Number of subjects: 745
Study: 32629123

Group type: EXPERIMENTAL
Intervention: Lean participants with NAFLD
Number of subjects: 3386

Group type: EXPERIMENTAL
Intervention: Lean Asian participants with NAFLD
Number of subjects: 3386
Study: 32629127

Group type: EXPERIMENTAL
Intervention: Enhanced Liver Fibrosis Score
Number of subjects: 0
Study: 32629625

Group type: EXPERIMENTAL
Intervention: Primary care clinical ultrasound classroom (AECAP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group of family physicians with similar characteristics
Number of subjects: 20
Study: 32629749

Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound elastography and MRI
Number of subjects: 0
Study: 32631100

Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) classification of AF image grids
Number of subjects: 35

Group type: COMPARATOR
Intervention: Support vector machines, traditional linear discriminant, and k-nearest neighbor analyses
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gradient-weighted class activation mapping applied to CNN
Number of subjects: 35
Study: 32631269

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Inadequate GWG
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Excessive GWG
Number of subjects: 3172
Study: 32631293

Group type: EXPERIMENTAL
Intervention: CPSP patients at 4 months post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: CPSP patients at 1 year post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: CPSP patients at 2 years post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: CPSP patients with mesh repair at 4 months post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: CPSP patients with non-mesh repair at 4 months post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: All patients at 2 years post-surgery
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: CPSP patients
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 1761
Study: 32631491

Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin 4 mg per mL; maximum 60 mg per instillation) administered via retrograde catheter to the renal pelvis and calyces, with six instillations once weekly.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: UGN-101
Number of subjects: 74
Study: 32631655

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation with nivolumab
Number of subjects: 10
Study: 32631787

Group type: EXPERIMENTAL
Intervention: Capecitabine with Aflibercept (Arm A, starting dose 1100 mg/m²)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Capecitabine with Aflibercept (recommended dose for phase II trials established at 1300 mg/m²)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study: 32631788

Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg every 2 weeks until progression or unacceptable toxicity
Number of subjects: 41
Study: 32632095

Group type: EXPERIMENTAL
Intervention: Descartes-08 (CD8+ anti-BCMA mRNA CAR T cells)
Number of subjects: 0
Study: 32632956

Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA) light treatment
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Intralesional interferon-α (IFN-α)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Bexarotene plus PUVA
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Subcutaneous IFN-α with acitretin or PUVA
Number of subjects: 1369

Group type: COMPARATOR
Intervention: PUVA maintenance treatment
Number of subjects: 1369
Study: 32633094

Group type: EXPERIMENTAL
Intervention: Swedish Orthostatic Hypotension Questionnaire (OHQ)
Number of subjects: 29
Study: 32633563

Group type: EXPERIMENTAL
Intervention: Combination of talimogene laherparepvec with atezolizumab
Number of subjects: 0
Study: 32633861

Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Number of subjects: 1631
Study: 32634066

Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 293
Study: 32634122

Group type: EXPERIMENTAL
Intervention: Presence of autoantibodies in ICL patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Detection of IgM and IgG anti-CD4+ cell antibodies
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Classical complement activation on CD4+ T cells
Number of subjects: 72
Study: 32634234

Group type: EXPERIMENTAL
Intervention: Sonidegib 400 mg daily + ruxolitinib 20 mg twice daily
Number of subjects: 50
Study: 32634238

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen of alemtuzumab, hydroxyurea, fludarabine, melphalan, and thiotepa with a single-unit umbilical cord blood graft.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen with single-unit umbilical cord blood graft.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Use of cord donor leukocyte infusion (cDLI) posttransplant.
Number of subjects: 44
Study: 32634435

Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Drug abuse
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Thoracic trauma
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Respiratory failure episodes
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: ICU length of stay (LOS)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Neurological outcome
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Age (hazard ratio)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Chest trauma (hazard ratio)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Histamine-receptor antagonist intake (hazard ratio)
Number of subjects: 962

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (hazard ratio)
Number of subjects: 962
Study: 32634461

Group type: EXPERIMENTAL
Intervention: Walking football program
Number of subjects: 31
Study: 32634610

Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg
Number of subjects: 0
Study: 32634611

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression
Number of subjects: 398
Study: 32634812

Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Phonological and semantic verbal fluency
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Standard Error of Measurement (SEM) and Minimum Detectable Change (MDC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cognitive modification assessment
Number of subjects: 81
Study: 32635158

Group type: EXPERIMENTAL
Intervention: Fluorescence sampling of the root canal space prior to obturation
Number of subjects: 65
Study: 32635224

Group type: EXPERIMENTAL
Intervention: Immune-related gene (IRG) expression analysis
Number of subjects: 71